Cancer Network (9/30, Conroy) reported, “First-line maintenance rucaparib (Rubraca) yielded higher progression-free survival (PFS) compared with placebo among patients with newly diagnosed ovarian cancer regardless of cytoreductive surgery outcome and was favored across all subgroups, according to the results of the phase 3 ATHENA-MONO study.” These results were presented at the International Gynecologic Cancer Society 2022 Annual Global Meeting.
